ReNeuron Group PLC (FRA:RQE1)

€ 0.034 0 (0%) Market Cap: 2.28 Mil Enterprise Value: -3.31 Mil PE Ratio: 0 PB Ratio: 0.80 GF Score: 0/100

Full Year 2022 ReNeuron Group PLC Earnings Call Transcript
Jul 04, 2022

€0.304 (-3.80%)

Earnings
ReNeuron Group PLC Investor Presentation Transcript
Feb 04, 2022
Half Year 2022 ReNeuron Group PLC Earnings Presentation Transcript
Nov 30, 2021
Half Year 2022 ReNeuron Group PLC Earnings Call Transcript
Nov 30, 2021

€1.07 (-2.73%)

Earnings
Full Year 2021 ReNeuron Group PLC Earnings Presentation Transcript
Jul 08, 2021
Half Year 2021 ReNeuron Group PLC Earnings Call Transcript
Jan 06, 2021

€1.03

Earnings
Full Year 2020 ReNeuron Group PLC Earnings Call Transcript
Jul 20, 2020

€1.47 (+2.73%)

Earnings
Half Year 2020 ReNeuron Group PLC Earnings Call Transcript
Dec 06, 2019

€1.54 (+6.94%)

Earnings
Full Year 2019 ReNeuron Group PLC Earnings Call Transcript
Jul 11, 2019

€2.57 (-9.51%)

Earnings

Half Year 2022 ReNeuron Group PLC Earnings Call Transcript

Nov 30, 2021 / 01:00PM GMT

Release Date Price: €1.07 (-2.73%)

Transcript

Olav Hellebo

ReNeuron Group plc - CEO & Director

Good afternoon, everyone. Wonderful to see so many people in the room. Welcome to the interim results for the 6 months from April to September for ReNeuron.

Before I get going, I'd like to introduce Catherine Isted, our CFO. She joined in the middle of October from Oxford BioMedica, where she was part of the finance leadership team and Head of Corporate Development and Investor Relations. So welcome, Catherine. And I'd like to introduce Professor Stefano Pluchino as well. I always say his name a little bit wrong, but he gets used to it. He joined us in May. So he's been around for about half a year now, but since this is the first time for most of you to see -- meet him, I'll introduce him today. He's a Professor of Regenerative Neuroimmunology at the University of Cambridge.

So with that, on the next slide, we have the disclaimer. We are a public company. And I'm going to give you a quick overview of ReNeuron here on the summary. We have deep experience in the areas of stem cells and exosomes. Our most advanced program is in

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.